BNET Industries
Market Cap:$285.3M
Last Fiscal Year Sales:$1.7M
- Public
- US
Dow Jones Description
We are a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, with exclusive worldwide commercial rights to two products. We believe that each of our products will address a large market with significant unmet medical needs by offering advantages over currently available therapies. Our product portfolio includes: Fanapt tm (iloperidone), a compound for the treatment of schizophrenia. On November 27, 2007, the FDA accepted a New Drug Application (NDA) for Fanapt tm for the treatment of schizophrenia. On May 6, 2009, the FDA granted U.S. marketing approval of Fanapt tm for the acute treatment of schizophrenia in adults. We expect to commercialize Fanapt tm with our own sales force and/or commercial partners in the United States and to seek partners for commercialization of the compound outside of the United States. We plan to make Fanapt tm available in pharmacies in the United States prior to the end of 2009. Holders of an NDA have 60 days after approval to file for patent term restoration under the Hatch-Waxman Act. We submitted our application for patent term restoration with respect to Fanapt tm on June 9, 2009. On July 30, 2009, we signed a Medicaid Rebate Agreement with the Secretary of Health and Human Services relating to the sale of Fanapt tm to Medicaid patients. ...
Number of Employees 24
Contact Information
9605 Medical Center Dr Ste 300
Rockville, Maryland 20850-6380
(240) 599-4500
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
3 Stocks to Battle a Double-Dip Recession
-
Jefferies Starts Vanda Pharma VNDA at Buy
-
Vanda Pharma Says Deal With Novartis On Rights To Fanapt Becomes Effective - Quick Facts
-
Vanda Pharmaceuticals receives $200M in Novartis deal
-
Vanda Pharmaceuticals Reports Third Quarter 2009 Results
-
New Schizophrenia drug set to debut in 2010
-
Vanda Pharmaceuticals Reports Third Quarter 2009 Results
-
Novartis Pharma Inks Pact with Vanda Pharmaceuticals for Commercialization of Fanapt in the U.S. and...
-
Week of Oct. 12, 2009: GSK and Prosensa Form Pact; Cardiokine Appoints CEO; More...
-
BioWatch: Baltimore biotech turns to the past for cutting-edge treatment
-
Vanda Inks $465M Novartis Deal, but Acquisition Not off the Table
-
Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009 --Conference Call...
-
Vanda Licenses Schizophrenia Drug To Novartis
-
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to FanaptTM, an FDA-Approved Oral...
-
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of FanaptTM...
-
Vanda, Oculus, Sequenom: Biotech Notebook
News & Analysis
Filter by
biotech and vanda pharmaceuticals inc. - All News and Analysis
Titan Pharma Stock Remains Primed to Spike
Seeking Alpha
- 2009-11-03
VFC submits: Titan Pharmaceuticals (TTNP.PK) was mentioned in a weekend article by the Washington Post that highlighted the CEO of Vanda Pharmaceuticals, Mihael Polymeropoulos, and Fanapt - Vanda's recently approved drug to treat schizophrenia of which Titan will reap up to 10% in royalties.While Novartis NVS emerged as Vanda's...
Vanda Headed Higher on Novartis Deal
Seeking Alpha
- 2009-10-13
VFC submits: Shares of Vanda Pharmaceuticals VNDA are set to trade to the upside on Tuesday after news was released on Monday evening detailing a licensing agreement with Novartis NVS for Fanapt that could be worth as much as $465 million. VNDA traded higher by 20% during the after...
Vanda Pharmaceuticals: Heavily Undervalued
Seeking Alpha
- 2009-07-08
Vanda Pharmaceuticals VNDA is making a stunning come back this year as FDA finally approved its schizophrenia drug Fanapt. But the story is far from over, and there is every reason to believe VNDA is still heavily undervalued and has huge upside potential. This is a potential giant market for...
Vanda Pharmaceuticals Comes Back from the Dead
Seeking Alpha
- 2009-07-01
Derek Lowe submits: I wrote last summer about Vanda Pharmaceuticals VNDA and their difficulty getting a new antipsychotic Fanapt iloperidone through the FDA. At the time, they'd received one of those wonderful requests for more information from the agency, of the kind that spread cheer whenever they appear. I...
Competitive Technologies, Aethlon Medical: Pain Relief Without the Pills
Seeking Alpha
- 2009-06-11
Danny Furman submits: I failed chemistry in college. My ego says it was because I didn't apply myself. Still I feel grossly inept when it comes to analyzing biotech stocks. I bought Vanda Pharmaceuticals VNDA near $1 because of their strong cash position, then sold at $1.23 to get my...
Titan Pharmaceuticals' Story Is Just Beginning
Seeking Alpha
- 2009-05-27
VFC submits: Titan Pharmaceuticals (TTNP.PK) rose another 25%, and may still rise further, after the recent FDA approval of Fanapt. Fanapt, produced by Vanda Pharmaceuticals VNDA to treat schizophrenia, is Titan's licensed product from which it will receive royalty payments of between 8%-10% from net sales of the product....
Vanda Pharmaceuticals: A Biotech Stock Worth Watching
Seeking Alpha
- 2009-05-27
VFC submits: During Tuesday's broad market rally, the action of a few stocks caught my attention and are worth watching for at least the rest of the week.Vanda Pharmaceuticals VNDA: by VFC's Stock House
Vanda Holding Up Well
Seeking Alpha
- 2009-05-22
VNDA: UPGRADED To $22 As equities reversed hard on Wednesday afternoon, one of the few stocks that held up well on my screen was biotech Vanda Pharmaceuticals VNDA. VNDA has been consolidating for the past two weeks between $10-12.5 after having run up 1000% after...
Vanda Snaps Up Victory from the Jaws of Defeat
Seeking Alpha
- 2009-05-08
Mike Huckman submits: Wednesday, Vanda Pharmaceuticals VNDA had a market value of $28 million. That's way too small to mention on CNBC, here on the blog or even on Twitter. But exceptions can be made when a company, even one that little, has real news. by Mike Huckman
Small-Cap Biotechs: How to Separate The Contenders From The Pretenders
Seeking Alpha
- 2009-05-08
Smart Profits Report submits: By Marc Lichtenfeld I’m used to explosive gains in the biotech world, but I’ve never seen a moonshot quite like this… by Smart Profits Report
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q10 (Qtr End11/30/09) Earnings Call Transcript
on Dec 18, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about WNI
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
Presented by American Express